Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11793379rdf:typepubmed:Citationlld:pubmed
pubmed-article:11793379lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:11793379lifeskim:mentionsumls-concept:C0026724lld:lifeskim
pubmed-article:11793379lifeskim:mentionsumls-concept:C1257852lld:lifeskim
pubmed-article:11793379lifeskim:mentionsumls-concept:C0020835lld:lifeskim
pubmed-article:11793379lifeskim:mentionsumls-concept:C0001561lld:lifeskim
pubmed-article:11793379lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:11793379pubmed:issue3lld:pubmed
pubmed-article:11793379pubmed:dateCreated2002-1-16lld:pubmed
pubmed-article:11793379pubmed:abstractTextConcanavalin A-immobilized polystyrene nanospheres (Con A-NS) were developed for the HIV-1 vaccine capable of preventing sexual transmission. Con A-NS could capture efficiently HIV-1 irrespective of their cell tropism (R5 or X4). Furthermore, Con A-NS captured equally infectious and heat-inactivated HIV-1. Inactivated HIV-1-capturing Con A-NS (HIV-NS) were intravaginally administered to mice. Heat-inactivated HIV-1 alone and Con A-NS alone were also administered as control immunogens. Vaginal fluids were collected during and after immunization and analyzed for their anti-HIV-1 antibody levels. Although the anti-HIV-1 IgG antibody was undetectable in any groups, increased anti-HIV-1 IgA antibody response was identified in the vaginal fluids of immunized mice with HIV-NS. The vaginal fluids obtained from the HIV-NS-administered mice showed neutralizing activity against the immunizing HIV-1 strain. A marked difference in vaginal distribution was observed between HIV-NS and other immunogens, and the toxicity of Con A was reduced by conjugation with nanospheres. Thus, HIV-NS may have great potential as a prophylactic HIV-1 vaccine and should be examined further for its efficacy in non-human primates.lld:pubmed
pubmed-article:11793379pubmed:languageenglld:pubmed
pubmed-article:11793379pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11793379pubmed:citationSubsetIMlld:pubmed
pubmed-article:11793379pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11793379pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11793379pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11793379pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11793379pubmed:statusMEDLINElld:pubmed
pubmed-article:11793379pubmed:monthMarlld:pubmed
pubmed-article:11793379pubmed:issn0146-6615lld:pubmed
pubmed-article:11793379pubmed:authorpubmed-author:SerizawaTakes...lld:pubmed
pubmed-article:11793379pubmed:authorpubmed-author:AkashiMitsuru...lld:pubmed
pubmed-article:11793379pubmed:authorpubmed-author:KawamuraMasak...lld:pubmed
pubmed-article:11793379pubmed:authorpubmed-author:NaitoTaichiTlld:pubmed
pubmed-article:11793379pubmed:authorpubmed-author:UenoMasamichi...lld:pubmed
pubmed-article:11793379pubmed:authorpubmed-author:AkagiTakamiTlld:pubmed
pubmed-article:11793379pubmed:authorpubmed-author:HiraishiKatsu...lld:pubmed
pubmed-article:11793379pubmed:authorpubmed-author:TakaiIzumiIlld:pubmed
pubmed-article:11793379pubmed:authorpubmed-author:MakinoMasahik...lld:pubmed
pubmed-article:11793379pubmed:authorpubmed-author:SugimuraKazuh...lld:pubmed
pubmed-article:11793379pubmed:authorpubmed-author:BabaMasanoriMlld:pubmed
pubmed-article:11793379pubmed:copyrightInfoCopyright 2002 Wiley-Liss, Inc.lld:pubmed
pubmed-article:11793379pubmed:issnTypePrintlld:pubmed
pubmed-article:11793379pubmed:volume66lld:pubmed
pubmed-article:11793379pubmed:ownerNLMlld:pubmed
pubmed-article:11793379pubmed:authorsCompleteYlld:pubmed
pubmed-article:11793379pubmed:pagination291-8lld:pubmed
pubmed-article:11793379pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:11793379pubmed:meshHeadingpubmed-meshheading:11793379...lld:pubmed
pubmed-article:11793379pubmed:meshHeadingpubmed-meshheading:11793379...lld:pubmed
pubmed-article:11793379pubmed:meshHeadingpubmed-meshheading:11793379...lld:pubmed
pubmed-article:11793379pubmed:meshHeadingpubmed-meshheading:11793379...lld:pubmed
pubmed-article:11793379pubmed:meshHeadingpubmed-meshheading:11793379...lld:pubmed
pubmed-article:11793379pubmed:meshHeadingpubmed-meshheading:11793379...lld:pubmed
pubmed-article:11793379pubmed:meshHeadingpubmed-meshheading:11793379...lld:pubmed
pubmed-article:11793379pubmed:meshHeadingpubmed-meshheading:11793379...lld:pubmed
pubmed-article:11793379pubmed:meshHeadingpubmed-meshheading:11793379...lld:pubmed
pubmed-article:11793379pubmed:meshHeadingpubmed-meshheading:11793379...lld:pubmed
pubmed-article:11793379pubmed:meshHeadingpubmed-meshheading:11793379...lld:pubmed
pubmed-article:11793379pubmed:meshHeadingpubmed-meshheading:11793379...lld:pubmed
pubmed-article:11793379pubmed:meshHeadingpubmed-meshheading:11793379...lld:pubmed
pubmed-article:11793379pubmed:meshHeadingpubmed-meshheading:11793379...lld:pubmed
pubmed-article:11793379pubmed:meshHeadingpubmed-meshheading:11793379...lld:pubmed
pubmed-article:11793379pubmed:year2002lld:pubmed
pubmed-article:11793379pubmed:articleTitleInduction of mucosal IgA following intravaginal administration of inactivated HIV-1-capturing nanospheres in mice.lld:pubmed
pubmed-article:11793379pubmed:affiliationDivision of Human Retroviruses, Center for Chronic Viral Diseases, Faculty of Medicine, Kagoshima University, Kagoshima, Japan.lld:pubmed
pubmed-article:11793379pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11793379lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11793379lld:pubmed